Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RNS System Feasibility Study of Thalamocortical Brain-Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome

NCT05339126 is registered in ClinicalTrials.gov with NeuroPace as lead sponsor.

NCT NCT05339126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05339126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RNS System Feasibility Study of Thalamocortical Brain-Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome
Lead sponsor
NeuroPace
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 4, 2022
Completion date
December 31, 2026
Enrollment
24 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, lennox gastaut syndrome, lennox-gastaut syndrome, intractable, seizures, seizures, generalized